These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17698234)

  • 61. Field production and functional evaluation of chloroplast-derived interferon-alpha2b.
    Arlen PA; Falconer R; Cherukumilli S; Cole A; Cole AM; Oishi KK; Daniell H
    Plant Biotechnol J; 2007 Jul; 5(4):511-25. PubMed ID: 17490449
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs.
    Zhan J; Chen Y; Yuan HY; Li H; Lu H
    Biotechnol Lett; 2012 Mar; 34(3):417-23. PubMed ID: 22083716
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Increasing the cell viability and heterologous protein expression of Pichia pastoris mutant deficient in PMR1 gene by culture condition optimization.
    Zhao HL; Xue C; Wang Y; Yao XQ; Liu ZM
    Appl Microbiol Biotechnol; 2008 Nov; 81(2):235-41. PubMed ID: 18751693
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative effects of stabilizing additives on the rates of heat inactivation of recombinant human interferon alpha-2b in solution.
    Sebeka HK; Starkuviene B; Trepsiene OV; Pauliukonis AA; Bumelis VA
    Antiviral Res; 2001 May; 50(2):117-27. PubMed ID: 11369432
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Functional expression of human serum albumin-tandem thrombopoietin mimetic peptide fusion protein as a novel thrombopoietin analog in Pichia pastoris.
    Wang M; Zhi D; Xian J; Ru Y; Wei S; Wang N; Liu Y; Wang H; Pei Y; Song M; Li Y; Li H
    Biotechnol Lett; 2016 May; 38(5):779-85. PubMed ID: 26857608
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
    Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impaired antiviral response in human hepatoma cells.
    Keskinen P; Nyqvist M; Sareneva T; Pirhonen J; Melén K; Julkunen I
    Virology; 1999 Oct; 263(2):364-75. PubMed ID: 10544109
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris.
    Dou WF; Lei JY; Zhang LF; Xu ZH; Chen Y; Jin J
    Protein Expr Purif; 2008 Sep; 61(1):45-9. PubMed ID: 18556214
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interferon immunogenicity: technical evaluation of interferon-alpha 2a.
    Hochuli E
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S15-21. PubMed ID: 9241611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Generation of a liver targeting fusion interferon and its bioactivity analysis in vitro.
    Cai G; Jiang M; Zhou Y; Gu X; Zhang B; Zou M; Zhou X; Bao J; Cao G; Zhang R
    Pharmazie; 2011 Oct; 66(10):761-5. PubMed ID: 22026157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A molecular approach to optimize hIFN α2b expression and secretion in Yarrowia lipolytica.
    Gasmi N; Fudalej F; Kallel H; Nicaud JM
    Appl Microbiol Biotechnol; 2011 Jan; 89(1):109-19. PubMed ID: 20821205
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recombinant protein hydrazides: application to site-specific protein PEGylation.
    Thom J; Anderson D; McGregor J; Cotton G
    Bioconjug Chem; 2011 Jun; 22(6):1017-20. PubMed ID: 21618993
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and interferon-modulating efficacy of a combination of rectal and topical dosage forms of interferon-α2b in acute respiratory infections.
    Kalyuzhin OV; Ponezheva ZB; Kupchenko AN; Shuvalov AN; Guseva TS; Parshina OV; Malinovskaya VV; Akimkin VG
    Ter Arkh; 2018 Nov; 90(11):48-54. PubMed ID: 30701815
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel fusion proteins of interferon alpha2b cause growth inhibition and induce JAK-STAT signaling in melanoma.
    Fernandes E; Soans E; Xu J; Kieliszewski M; Evans SC
    J Immunother; 2010 Jun; 33(5):461-6. PubMed ID: 20463602
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Purification and activity assay of HSA-AX15 (R13K) fusion protein expressed in Pichia pastoris].
    Zhao HL; Xue C; Xiong XH; Zhang W; Yang BF; Liu ZM
    Sheng Wu Gong Cheng Xue Bao; 2005 Mar; 21(2):254-8. PubMed ID: 16013485
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit.
    Ceaglio N; Gugliotta A; Tardivo MB; Cravero D; Etcheverrigaray M; Kratje R; Oggero M
    J Biotechnol; 2016 Mar; 221():13-24. PubMed ID: 26806490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.